cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Mannkind Corp
26 own
42 watching
Current Price
$5.31
$0.01
(0.19%)
logo-mnkd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,397.36M
52-Week High
52-Week High
5.465
52-Week Low
52-Week Low
2.49
Average Volume
Average Volume
2.64M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,397.36M
icon52-Week High5.465
icon52-Week Low2.49
iconAverage Volume2.64M
iconDividend Yield--
iconP/E Ratio--
What does the Mannkind Corp do?
MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes diseases in the United States. Its approved product is Afrezza, a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type 2 diabetes. The company was founded in 1991 and is based in Valencia, California.
Read More
How much money does Mannkind Corp make?
News & Events about Mannkind Corp.
Globe Newswire
2 months ago
Conference Call to Begin Today at 9:00 a.m. (ET)3Q 2022 Total Revenues of $32.8 million; +48% vs. 3Q 20213Q 2022 Royalties from Tyvaso DPI of $6.2 million3Q 2022 Commercial Products Net Revenue of $16.3 million; +67% vs. 3Q 2021 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Nov. 08, 2022 (GLOBE ...
Simply Wall St
4 months ago
A look at the shareholders of MannKind Corporation ( NASDAQ:MNKD ) can tell us which group is most powerful. And the...
Globe Newswire
7 months ago
WESTLAKE VILLAGE, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative therapeutic products for patients with endocrine and orphan lung diseases, will showcase its mealtime insulin solutions and ...
Zolmax
8 months ago
Principal Financial Group Inc. lessened its holdings in shares of MannKind Co. (NASDAQ:MNKD Get Rating) by 11.0% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 338,126 shares of the biopharmaceutical companys stock after ...
Ticker Report
8 months ago
Citigroup Inc. raised its stake in MannKind Co. (NASDAQ:MNKD Get Rating) by 88.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 671,215 shares of the biopharmaceutical companys stock after buying an additional 315,097 shares during the quarter. Citigroup Inc.s...
Frequently Asked Questions
Frequently Asked Questions
What is Mannkind Corp share price today?
plus_minus_icon
Can Indians buy Mannkind Corp shares?
plus_minus_icon
How can I buy Mannkind Corp shares from India?
plus_minus_icon
Can Fractional shares of Mannkind Corp be purchased?
plus_minus_icon
What are the documents required to start investing in Mannkind Corp stocks?
plus_minus_icon
What is today’s traded volume of Mannkind Corp?
plus_minus_icon
What is today’s market capitalisation of Mannkind Corp?
plus_minus_icon
What is the 52-Week High and Low Range of Mannkind Corp?
plus_minus_icon
What percentage is Mannkind Corp down from its 52-Week High?
plus_minus_icon
What percentage is Mannkind Corp up from its 52-Week Low?
plus_minus_icon
Current Price
$5.31
$0.01
(0.19%)
logo-mnkd
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00